The IL-33 monoclonal antibody developed through cooperation between Sanofi (SNY.US) and Regeneron (REGN.US) has received clinical approval in China for the treatment of chronic rhinosinusitis.

Today (January 15), the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that the 1st class new drug itepekimab injection declared by Sanofi (SNY.US) has been approved for clinical trials, intended for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) patients. Public information shows that this is a monoclonal antibody targeting IL33, developed in collaboration between Sanofi and Regeneron (REGN.US). The product has previously obtained implicit approval for multiple clinical trials in China, with indications including the treatment of non-cystic fibrosis bronchiectasis (NCFB) and moderate to severe chronic obstructive pulmonary disease (COPD) patients as an additional maintenance therapy. Screenshot source: CDE official website Interleukin-33 (IL-33) is a widely acting IL-1 family cytokine, released from stressed or damaged barrier tissues (including endothelial and epithelial cells) after external factors such as trauma, allergen exposure, or infection trigger it. Under normal physiological conditions, IL-33 can initiate a protective immune response, however, excess release of IL-33 or chronic signaling can also drive tissue-damaging inflammation. Studies have shown that IL-33 dysregulation may be associated with the pathology of various inflammatory diseases and severe infectious diseases. The therapeutic potential of anti-IL-33 antibodies has been preliminarily validated in research targeting asthma, atopic dermatitis, food allergies, and other diseases.